Today: 7 February 2026
Subscribe
Browse Category

Pharma News News 18 January 2026 - 3 February 2026

Liminatus Pharma (LIMN) jumps in premarket after late-session spike as Nasdaq $1 rule hangs over shares

Liminatus Pharma (LIMN) jumps in premarket after late-session spike as Nasdaq $1 rule hangs over shares

Liminatus Pharma shares jumped 29.4% to $0.74 in premarket trading Tuesday after surging 64.6% to $0.94 in Monday’s after-hours session. The stock remains below the $1 minimum required for Nasdaq listing, with the company facing a July 14, 2026 deadline to regain compliance. Liminatus disclosed it received a Nasdaq deficiency notice in January. Market cap stood near $15.5 million.
3 February 2026
····
Eli Lilly stock climbs after $3.5 billion Pennsylvania plant plan as investors eye earnings

Eli Lilly stock climbs after $3.5 billion Pennsylvania plant plan as investors eye earnings

Eli Lilly shares rose 1.6% to $1,040.80 midday Friday after announcing a $3.5 billion injectable drug plant near Allentown, Pennsylvania, set to open by 2031. Pennsylvania will provide $100 million for the project. Lilly also signed a $1.93 billion autoimmune research deal with Repertoire. Quarterly results are due Feb. 4.
30 January 2026
·····
Gilead stock dips as Medicare targets Biktarvy for 2028 price talks — and Trodelvy gets a guideline lift

Gilead stock dips as Medicare targets Biktarvy for 2028 price talks — and Trodelvy gets a guideline lift

Gilead Sciences shares fell 1.3% to $139.19 Wednesday afternoon after Medicare named its HIV drug Biktarvy for 2026 price negotiations, with caps set to start in 2028. The company also reported its cancer drug Trodelvy was upgraded to “category 1” in new NCCN breast cancer guidelines. Investors await Gilead’s earnings on Feb. 10.
28 January 2026
··
CRISPR Therapeutics stock in focus as shares cool premarket after 11% surge and CEO sale filing

CRISPR Therapeutics stock in focus as shares cool premarket after 11% surge and CEO sale filing

New York, Jan 23, 2026, 05:47 (EST) — Premarket CRISPR Therapeutics AG shares slipped about 0.5% to $60.51 in premarket trading on Friday, following a sharp 11.1% gain the previous day. The stock closed at $60.81 on Thursday after hitting an intraday high of $60.86 and seeing over 3.4 million shares change hands. Investors were reacting to an insider-sale filing. (Public) The move highlighted just how volatile the stock remains. CRISPR is behaving more like a high-beta biotech than a reliable cash-flow play, with the tape influencing the price as much as its pipeline does. That’s crucial now, as investors
23 January 2026
····
Novo Nordisk stock price jumps before the bell as Wegovy pill prescriptions leap

Novo Nordisk stock price jumps before the bell as Wegovy pill prescriptions leap

New York, January 23, 2026, 05:29 EST — Premarket Novo Nordisk A/S (NVO) shares jumped 4.9% to $62.23 in premarket trading Friday following new data revealing a strong surge in U.S. prescriptions for its Wegovy weight-loss drug. The stock closed Thursday at $59.32. The numbers matter because investors now use weekly prescription data as a near-real-time indicator of demand for new obesity drugs, well ahead of quarterly sales reports. Novo is fighting to hold its ground in the GLP-1 drug space — medications that suppress appetite and regulate blood sugar — as competitors ramp up their efforts. The market, meanwhile,
23 January 2026
·····
Moderna stock jumps again as Merck cancer vaccine data keeps MRNA rally running

Moderna stock jumps again as Merck cancer vaccine data keeps MRNA rally running

New York, Jan 22, 2026, 10:15 EST — Regular session Moderna shares climbed 7.7% to $53.65 Thursday morning, extending gains fueled by fresh long-term data on its experimental personalized cancer vaccine, created in partnership with Merck. Moderna’s push is vital as it aims to convince investors it can thrive beyond COVID vaccines. A promising mid-stage oncology trial could swiftly shift investor sentiment. Wall Street opened sharply higher after President Donald Trump softened his stance on tariffs targeting European countries. The Dow surged 0.81%, and the S&P 500 climbed 0.70% at the start of trading. (Reuters) Moderna and Merck revealed Tuesday
22 January 2026
····
Eternal CEO Exit, Ozempic Generic Nod, Waaree Profit Surge: India’s Q3 Results Move Stocks

Eternal CEO Exit, Ozempic Generic Nod, Waaree Profit Surge: India’s Q3 Results Move Stocks

Mumbai, Jan 22, 2026, 16:16 IST Eternal shares swung on Thursday as investors weighed a CEO handover and a fresh set of quarterly numbers, setting the tone for a packed run of December-quarter earnings in India. The results matter because they cut across the parts of the economy that have been driving stock moves: instant delivery, drug exports and domestic healthcare, and energy margins. Investors are also watching banks for early hints on credit costs and deposit competition. Upstox said dozens of firms were due to report for the quarter ended December 2025, including Eternal, Dr Reddy’s Laboratories, Hindustan Petroleum,
22 January 2026
·····
Moderna stock (MRNA) steadies in premarket after 16% surge on Merck cancer-vaccine data

Moderna stock (MRNA) steadies in premarket after 16% surge on Merck cancer-vaccine data

New York, Jan 22, 2026, 04:51 EST — Premarket. Moderna shares were flat at $49.81 in premarket trading on Thursday, after the stock jumped 15.8% in the previous session. (Yahoo Finance) The rally followed fresh five-year follow-up data on Moderna’s experimental personalised cancer vaccine used with Merck’s blockbuster immunotherapy Keytruda in high-risk melanoma, the companies said. (Merck.com) The move matters because Moderna is still trying to replace shrinking COVID-19 vaccine revenue with new products. Investors have been quick to reward any sign its mRNA technology can travel well beyond respiratory shots. In the update, the companies said the vaccine-Keytruda combination
22 January 2026
······
Novavax stock edges up premarket as Pfizer Matrix‑M pact puts $530 million-plus in play

Novavax stock edges up premarket as Pfizer Matrix‑M pact puts $530 million-plus in play

New York, January 21, 2026, 05:22 EST — Premarket Novavax shares edged higher by about 1% in premarket Wednesday after announcing a licensing agreement with Pfizer for its Matrix‑M vaccine technology. The stock last changed hands at $8.28, marking a 0.98% increase. (Public) Novavax’s deal is significant as the company looks to pivot its platform toward steadier revenue sources amid a drop in pandemic vaccine sales. Investors are increasingly focused on partnerships that bring upfront payments plus ongoing royalties, moving away from relying solely on seasonal demand surges. Pfizer is zeroing in on Matrix‑M, an adjuvant that amplifies the immune
21 January 2026
······
Eli Lilly stock ticks up after FDA “breakthrough” tag for ovarian cancer drug

Eli Lilly stock ticks up after FDA “breakthrough” tag for ovarian cancer drug

New York, Jan 20, 2026, 6:50 PM EST — After-hours Eli Lilly’s shares edged up 0.3% to close Tuesday at $1,041.29, then ticked 0.04% higher in after-hours action. The move followed news that the U.S. FDA granted Breakthrough Therapy designation to its ovarian cancer drug candidate, sofetabart mipitecan. (MarketScreener) The change is slight, but it hits home as investors keep their eyes on Lilly’s pipeline beyond its blockbuster diabetes and obesity treatments. With the stock already factoring in perfect execution, even a hint of new growth potential makes an impact. The designation focuses on a hard-to-treat group of adults with
21 January 2026
·····
Eli Lilly stock price: What to watch after Friday’s close as FDA review scrutiny and Novo’s pill data hit

Eli Lilly stock price: What to watch after Friday’s close as FDA review scrutiny and Novo’s pill data hit

New York, January 18, 2026, 10:06 EST — Market closed Eli Lilly shares ended Friday at $1,038.40, rising 0.5% after fluctuating between $1,019 and $1,049.83 during the session. With U.S. markets shut for the weekend, traders are left to digest regulatory and competitive developments ahead of Monday’s open. Why it matters now: Lilly’s next valuation boost hinges on weight loss, and investors are weighing two fresh signals — the speed of the U.S. drug regulator’s action, and whether pills can expand demand beyond injections. The setup is more delicate than it appears. Speeding up the timeline for a new oral
18 January 2026
······
1 2 3 … 11

Stock Market Today

Seagate (STX) stock jumps nearly 6% as Citi hikes target — what to watch next week

Seagate (STX) stock jumps nearly 6% as Citi hikes target — what to watch next week

7 February 2026
Seagate shares rose 5.9% to $429.32 Friday after Citigroup raised its price target to $480 and reiterated a buy rating. The gain ended a two-day slide but left the stock 6.6% below its Feb. 3 high. CEO Dave Mosley sold 20,000 shares on Feb. 2 under a pre-arranged plan, SEC filings show. U.S. jobs and inflation data next week are seen as key tests for tech stocks.
Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

7 February 2026
Cummins shares jumped 6.8% to $577.73 Friday, recovering from a nearly 9% post-earnings drop the day before. The company reported Q4 revenue up 1% to $8.54 billion, took a $218 million charge tied to its hydrogen business, and guided for 2026 EBITDA of 17–18% of sales. Demand for data center generators offset weakness in North American truck markets. Analyst reaction was mixed; Truist raised its price target.
Corning stock hits first record close since 2000 as jobs, CPI data loom

Corning stock hits first record close since 2000 as jobs, CPI data loom

7 February 2026
Corning shares surged 8.3% to $122.16 Friday, their highest close since the dot-com era, after Meta agreed to buy up to $6 billion in fiber-optic cables. The stock is up 40% since late 2025, fueled by strong first-quarter guidance and AI data-center demand. Insiders sold shares following the rally, SEC filings show. Investors await next week’s U.S. jobs and inflation data for rate signals.
Go toTop